Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on September 12, 2006. The filing addresses a material definitive agreement regarding the adjustment of equity compensation for non-employee members of the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and compensation policy changes rather than financial performance.
Material Changes
The Board of Directors approved an increase in equity compensation for non-employee directors under the 2004 Stock Incentive Plan, effective September 12, 2006. The specific changes are:
- Initial Grant: New non-employee directors will receive an option to purchase 30,000 shares of common stock upon commencement of service (an increase of 5,000 shares).
- Annual Grant: Eligible non-employee directors will receive an option to purchase 15,000 shares of common stock at each annual meeting starting in 2007 (an increase of 5,000 shares).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary on business operations. The adjustment was made following a review of market compensation data deemed appropriate by the Board. No specific risks or contingencies related to financial performance were disclosed in this document.
Investor Verification Points
- Verify the total number of shares authorized under the 2004 Stock Incentive Plan to assess the impact of these increased grants.
- Review the vesting schedules and exercise terms for the new 30,000 and 15,000 share options.
- Confirm the number of current non-employee directors to estimate the immediate dilution impact.